Article
Oncology
Xu-Dong Tang, Kui-Lin Lu, Jin Yu, Han-Jian Du, Chao-Qiang Fan, Lei Chen
Summary: This study establishes a novel immunotherapy model targeting antigens to dendritic cell receptors using a combination of heparanase CD4(+) and CD8(+) T-cell epitope peptides, achieving an efficient cytotoxic T-cell response against tumor cells.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Medicine, General & Internal
Tatiana M. Garcia-Bates, Mariana L. Palma, Renee R. Anderko, Denise C. Hsu, Jintanat Ananworanich, Bette T. Korber, Gaurav D. Gaiha, Nittaya Phanuphak, Rasmi Thomas, Sodsai Tovanabutra, Bruce D. Walker, John W. Mellors, Paolo A. Piazza, Eugene Kroon, Sharon A. Riddler, Nelson L. Michael, Charles R. Rinaldo, Robbie B. Mailliard
Summary: The study demonstrated the efficacy of using MDC1 to selectively elicit CTL responses against conserved and topologically important HIV-1 epitopes. Epigraph and Network antigens showed higher sequence conservation and stronger CTL responses compared to overlapping Gag peptides. Importantly, CTL responses against topologically constrained Gag epitopes were enhanced in Network pool-initiated cultures.
Article
Oncology
Anastasia Prokopi, Christoph H. Tripp, Bart Tummers, Florian Hornsteiner, Sarah Spoeck, Jeremy Chase Crawford, Derek R. Clements, Mirjana Efremova, Katharina Hutter, Lydia Bellmann, Giuseppe Cappellano, Bruno L. Cadilha, Sebastian Kobold, Louis Boon, Daniela Ortner, Zlatko Trajanoski, Suzie Chen, Tanja D. de Gruijl, Juliana Idoyaga, Douglas R. Green, Patrizia Stoitzner
Summary: Immunotherapy with checkpoint inhibitors has shown impressive results in patients with melanoma, but many still do not benefit from this treatment due to factors such as lack of tumor-infiltrating T cells and loss of intratumoral dendritic cells. In a melanoma mouse model, researchers found that tumor progression is characterized by upregulation of checkpoint molecules and gradual loss of dermal conventional DC 2 subset. Monotherapy with checkpoint blockade was not effective, but boosting DC numbers and activation increased tumor immunogenicity, leading to improved T cell function and delayed tumor growth when combined with antibodies against PD-1 and TIM-3. The study highlights the importance of skin DC in cancer immunotherapy and suggests that restoring DC function is key to enhancing tumor immunogenicity and responsiveness to checkpoint blockade therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Medicine, Research & Experimental
Zhanbo Sun, Lingyun Zhang, Lixian Liu
Summary: This article summarizes the lipid metabolism of dendritic cells (DCs) under physiological conditions, analyzes the role of reprogramming the lipid metabolism of DCs in tumor immune regulation, and discusses potential immunotherapeutic strategies.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Oncology
Hiroko Nakajima, Jun Nakata, Kanako Imafuku, Hiromu Hayashibara, Kazuki Isokawa, Keiko Udaka, Fumihiro Fujiki, Soyoko Morimoto, Kana Hasegawa, Naoki Hosen, Yoshiko Hashii, Sumiyuki Nishida, Akihiro Tsuboi, Yoshihiro Oka, Yusuke Oji, Shinji Sogo, Haruo Sugiyama
Summary: This study identified three novel mouse Th epitope peptides that strongly induced and maintained WT1-specific CTLs, efficiently rejected WT1-expressing tumor cells, and showed that these CTLs played a central role in tumor rejection. The majority of WT1-specific CTLs induced by the co-immunization with WT1 CTL and the WT1-specific Th peptides were effector memory CD8(+) T cells, demonstrating their essential function in WT1-specific tumor immunity.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Immunology
Jiayi Pan, Wuyi Zeng, Jiangtao Jia, Yi Shi, Danni Wang, Jun Dong, Zixuan Fang, Jiashan He, Xinyu Yang, Rong Zhang, Menghua He, Maoping Huang, Bishi Fu, Bei Zhong, Hui Liu
Summary: Dendritic cells (DCs), as professional antigen-presenting cells, play a crucial role in cancer treatment. DC vaccines have been widely studied for their therapeutic effects on cancer. However, the overall clinical efficacy of DC vaccines is not satisfactory, and there is a need to enhance their efficacy. In this study, a novel therapeutic MUC1-Vax tumor vaccine was developed based on the immune checkpoint PD-L1 and tumor-associated antigen MUC1. The vaccine demonstrated a strong anti-tumor effect in immunized mice.
Article
Chemistry, Multidisciplinary
Xueying Tang, Jiashuo Zhang, Dezhi Sui, Qiongfen Yang, Tianyu Wang, Zihan Xu, Xiaoya Li, Xin Gao, Xinyang Yan, Xinrong Liu, Yanzhi Song, Yihui Deng
Summary: This study developed a SA-modified mRNA vaccine that achieved successful DC targeting and efficient endosomal/lysosomal escape, resulting in higher transfection efficiency and lower side effects in DCs.
JOURNAL OF CONTROLLED RELEASE
(2023)
Article
Biochemistry & Molecular Biology
Tsutomu Nakazawa, Ryosuke Maeoka, Takayuki Morimoto, Ryosuke Matsuda, Mitsutoshi Nakamura, Fumihiko Nishimura, Shuichi Yamada, Ichiro Nakagawa, Young-Soo Park, Hiroyuki Nakase, Takahiro Tsujimura
Summary: This study investigated the capability of human induced pluripotent stem cells (iPSCs) lysate-pulsed dendritic cells (DCs) to induce cancer-responsive cytotoxic T lymphocytes (CTLs) in vitro. The results demonstrated that the iPSCs/DCs induced sufficient CTL numbers that responded to specific cancer cells, suggesting the potential of iPSC/DCs as a promising universal cancer vaccine.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Chemistry, Multidisciplinary
Tianqun Lang, Zhong Zheng, Xin Huang, Yiran Liu, Yihui Zhai, Pengcheng Zhang, Yaping Li, Qi Yin
Summary: A new combination therapy strategy using a specific cell and drug carrier to enhance drug concentration in tumors, alleviate immunosuppression, increase the infiltration and activity of CD8(+) T cells, suppress lung metastasis, and prolong the survival of mice.
ADVANCED FUNCTIONAL MATERIALS
(2021)
Article
Oncology
Zining Wang, Feifei Xu, Jie Hu, Hongxia Zhang, Lei Cui, Wenhua Lu, Wenzhuo He, Xiaojuan Wang, Mengyun Li, Huanling Zhang, Wenjing Xiong, Chunyuan Xie, Yongxiang Liu, Penghui Zhou, Jinyun Liu, Peng Huang, Xiaofeng Frank Qin, Xiaojun Xia
Summary: Clotrimazole was identified as a drug that could enhance DC-mediated antigen presentation and T cell response, by acting on hexokinase 2 to regulate metabolic production and enhancing the lysosome pathway and Chop expression in DCs. In vivo administration of clotrimazole induced immune infiltration and inhibited tumor growth, synergizing with anti-PD1 antibody therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Pavlina Chuntova, Yafei Hou, Ryosuke Naka, Akane Yamamichi, Tiffany Chen, Yitzhar Goretsky, Ryusuke Hatae, Takahide Nejo, Gary Kohanbash, Abigail L. Mende, Megan Montoya, Kira M. Downey, David Diebold, Jayne Skinner, Hong-Erh Liang, Bjoern Schwer, Hideho Okada
Summary: This study developed a new transgenic mouse model, which can be used to address clinically relevant questions and develop future immunotherapeutic strategies.
Article
Immunology
Yifang Shui, Xin Hu, Hiroshi Hirano, Kisato Kusano, Hirotake Tsukamoto, Mengquan Li, Kenichiro Hasumi, Wen-Zhi Guo, Xiao-Kang Li
Summary: Dendritic cells play a crucial role in the immune response against tumors, but can be influenced by an immunosuppressive environment. Aureobasidium pullulan-derived beta-glucan has shown potential in enhancing the anti-tumoral activity of dendritic cells and inhibiting tumor growth.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Immunology
Joao Calmeiro, Luis Mendes, Iola F. Duarte, Catarina Leitao, Adriana R. Tavares, Daniel Alexandre Ferreira, Celia Gomes, Joao Serra, Amilcar Falcao, Maria Teresa Cruz, Mylene A. Carrascal, Bruno Miguel Neves
Summary: This study compared the impact of different clinical grade serum-free media on dendritic cell differentiation, showing that dendritic cells differentiated in AIM-V or X-VIVO 15 exhibited better mature phenotype and immune activation capacity. Metabolomic analysis revealed that the enhanced DC immunostimulatory capacities were associated with increased catabolism of amino acids and glucose.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Qingyu Huang, Fuhao Wang, Di Hao, Xinyu Li, Xiaohui Li, Tianyu Lei, Jinbo Yue, Chao Liu
Summary: Dendritic cells play a pivotal role in connecting innate and adaptive immunity. The application of single-cell sequencing has revealed the heterogeneity and functional diversity of dendritic cells in the tumor microenvironment, providing important insights into tumor immune responses.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Byeong Hoon Kang, Heung Kyu Lee
Summary: Dendritic cells play a crucial role in immune responses and can activate cytotoxic T lymphocytes to kill tumor cells. Dendritic cell-based cancer immunotherapy has clinical benefits, but the immunogenicity and heterogeneity of tumors affect the success of this therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)